Approved regulatory verdict
Evidence outlook
Approved: Atopic Dermatitis, Crohn's Disease, Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis (label: moderately to severely active UC or CD who have had an inadequate response, lost response or were...)
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development: Systemic Lupus Erythematosus · Phase 3
How the evidence outlook works ↗
Featured trials The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Atopic Dermatitis · approved · Featured evidence · 3 Rheumatoid Arthritis · approved · Featured evidence · 3 Crohn's Disease · approved · Featured evidence · 2 Ulcerative Colitis · approved · Featured evidence · 2 Systemic Lupus Erythematosus · investigational · Featured evidence · 1 approved Featured evidence · 3
Competitive landscape 257 competitors in this universe: 12 direct rivals (same mechanism and indication), 2 same-class, 243 same-indication.
Unlock with Research ↗ Drug Stage Modality Mechanism Evidence signal Reported efficacygraded featured trials Upadacitinib (Rinvoq): this drug Approved Small molecule JAK, JAK1 Abrocitinib (Cibinqo)Approved Small molecule JAK1 Baricitinib (Olumiant)Approved Small molecule JAK , JAK1/2 Tofacitinib (Xeljanz)Approved Small molecule JAK , JAK1/JAK3 Filgotinib (Jyseleca)Phase 3 Small molecule JAK , JAK1 LNK01001 Phase 3 Small molecule JAK1 LW402 Phase 3 Small molecule JAK1 QLM3003 Phase 3 Small molecule JAK VC005 Phase 3 Small molecule JAK1 , JAK1 GSK2586184 Phase 2 Small molecule JAK1 , JAK1 IN-115314 Phase 2 Small molecule JAK1 JYP0061 Phase 2 Small molecule JAK1 ZL-82 Phase 2 Small molecule JAK AZD4604 Phase 2 — JAK1 AZD0449 Phase 1 — JAK1 Abatacept (Orencia)Approved Protein / enzyme therapeutic CD80/CD86 (CTLA-4-Ig) , Selective T Cell Costimulation Modulator , CD80/CD86 (B7-1/B7-2) on antigen-presenting cells
…and 242 more. Research shows the complete landscape.
Research Unlock the full comparison Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Unlock with Research ↗ Compare head-to-head
5 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events (43 total) Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (4) December 2026 (4) Phase 3 Long COVID Recruiting
Est. primary completion 2026-12 ·
NCT06928272 ·
CT.gov ↗ What to watch Phase 2 Primary Sjögren's Syndrome (pSS) Not yet recruiting
Est. primary completion 2026-12-30 ·
NCT06862284 ·
CT.gov ↗ What to watch Phase 3 Crohn's Disease Not yet recruiting
Est. primary completion 2026-12-31 ·
NCT07149467 ·
CT.gov ↗ What to watch Phase 4 Crohn's Disease Recruiting
Est. primary completion 2026-12-31 ·
NCT06520397 ·
CT.gov ↗ What to watch 2027 (16) January 2027 (1) Phase 3 Atopic Dermatitis Active not recruiting
Est. primary completion 2027-01 ·
NCT06701331 ·
CT.gov ↗ What to watch March 2027 (3) Phase 3 Systemic Lupus Erythematosus Active not recruiting
Est. primary completion 2027-03 ·
NCT05843643 ·
CT.gov ↗ What to watch Phase 4 Rheumatoid Arthritis Not yet recruiting
Est. primary completion 2027-03-05 ·
NCT07636057 ·
CT.gov ↗ What to watch Phase 4 Ulcerative Colitis Recruiting
Est. primary completion 2027-03-30 ·
NCT07546097 ·
CT.gov ↗ What to watch May 2027 (2) Phase 3 Ulcerative Colitis Recruiting
Est. primary completion 2027-05 ·
NCT06660693 ·
CT.gov ↗ What to watch Phase 4 Axial Spondylarthritis (axSpA) Not yet recruiting
Est. primary completion 2027-05 ·
NCT07018206 ·
CT.gov ↗ What to watch June 2027 (3) Phase 1 Eyelid Dermatitis Recruiting
Est. primary completion 2027-06 ·
NCT06684522 ·
CT.gov ↗ What to watch Phase 3 Crohn's Disease Recruiting
Est. primary completion 2027-06 ·
NCT06332534 ·
CT.gov ↗ What to watch Phase 3 Crohn's Disease Recruiting
Est. primary completion 2027-06-08 ·
NCT06227910 ·
CT.gov ↗ What to watch July 2027 (3) Phase 3 Ulcerative Colitis Active not recruiting
Est. primary completion 2027-07 ·
NCT03006068 ·
CT.gov ↗ What to watch Phase 2 Hidradenitis Suppurativa (Acne Inversa) Active not recruiting
Est. primary completion 2027-07-01 ·
NCT07727889 ·
CT.gov ↗ What to watch Phase 2 Immune Thrombocytopenia Not yet recruiting
Est. primary completion 2027-07-30 ·
NCT07064889 ·
CT.gov ↗ What to watch September 2027 (1) Phase 3 Crohn's Disease Active not recruiting
Est. primary completion 2027-09 ·
NCT03345823 ·
CT.gov ↗ What to watch November 2027 (2) Phase 4 Ulcerative Colitis Recruiting
Est. primary completion 2027-11 ·
NCT05867329 ·
CT.gov ↗ What to watch Phase 2 Atopic Dermatitis Not yet recruiting
Est. primary completion 2027-11-30 ·
NCT07678645 ·
CT.gov ↗ What to watch December 2027 (1) Phase 4 Uveitis Active not recruiting
Est. primary completion 2027-12-31 ·
NCT07773623 ·
CT.gov ↗ What to watch 2028 (13) January 2028 (1) Phase 2 Rheumatic Disease Recruiting
Est. primary completion 2028-01 ·
NCT07138898 ·
CT.gov ↗ What to watch March 2028 (2) Phase 3 Vitiligo Active not recruiting
Est. primary completion 2028-03 ·
NCT06118411 ·
CT.gov ↗ What to watch Phase 3 Hidradenitis Suppurativa Active not recruiting
Est. primary completion 2028-03 ·
NCT05889182 ·
CT.gov ↗ What to watch April 2028 (1) Phase 4 Ulcerative Colitis Recruiting
Est. primary completion 2028-04-01 ·
NCT07550673 ·
CT.gov ↗ What to watch May 2028 (1) Phase 2 Lichen Penis Planus Recruiting
Est. primary completion 2028-05-01 ·
NCT07492251 ·
CT.gov ↗ What to watch August 2028 (3) Phase 1/2 JAK1 GOF, STAT1 GOF, STAT3 GOF, STAT5B GOF, STAT6 GOF Not yet recruiting
Est. primary completion 2028-08 ·
NCT07670156 ·
CT.gov ↗ What to watch Phase 3 Ulcerative Colitis Active not recruiting
Est. primary completion 2028-08 ·
NCT05782907 ·
CT.gov ↗ What to watch Phase 3 Takayasu Arteritis (TAK) Active not recruiting
Est. primary completion 2028-08 ·
NCT04161898 ·
CT.gov ↗ What to watch September 2028 (2) Phase 4 Psoriatic Arthritis Recruiting
Est. primary completion 2028-09 ·
NCT06454188 ·
CT.gov ↗ What to watch Phase 4 Axial Spondyloarthritis (AxSpA) Not yet recruiting
Est. primary completion 2028-09-15 ·
NCT07770646 ·
CT.gov ↗ What to watch December 2028 (3) Phase 1 Juvenile Idiopathic Arthritis (JIA) Active not recruiting
Est. primary completion 2028-12 ·
NCT03725007 ·
CT.gov ↗ What to watch Phase 4 Ulcerative Colitis Not yet recruiting
Est. primary completion 2028-12-01 ·
NCT07502339 ·
CT.gov ↗ What to watch Phase 4 Crohn's Disease Recruiting
Est. primary completion 2028-12-31 ·
NCT07510191 ·
CT.gov ↗ What to watch 2029 (5) February 2029 (1) Phase 3 Alopecia Areata Active not recruiting
Est. primary completion 2029-02 ·
NCT07023302 ·
CT.gov ↗ What to watch April 2029 (1) Phase 4 Rheumatoid Arthritis Recruiting
Est. primary completion 2029-04-01 ·
NCT06687551 ·
CT.gov ↗ What to watch June 2029 (1) Phase 3 Juvenile Idiopathic Arthritis Recruiting
Est. primary completion 2029-06 ·
NCT05609630 ·
CT.gov ↗ What to watch November 2029 (1) Phase 4 Ulcerative Colitis Not yet recruiting
Est. primary completion 2029-11 ·
NCT07700446 ·
CT.gov ↗ What to watch December 2029 (1) Phase 4 Ulcerative Colitis Recruiting
Est. primary completion 2029-12 ·
NCT07258771 ·
CT.gov ↗ What to watch 2030 (4) February 2030 (1) Phase 2 EoE, Eosinophilic Esophagitis, Eosinophilic Esophagitis (EoE) Not yet recruiting
Est. primary completion 2030-02 ·
NCT07588568 ·
CT.gov ↗ What to watch April 2030 (1) Phase 3 Alopecia Areata Recruiting
Est. primary completion 2030-04 ·
NCT06012240 ·
CT.gov ↗ What to watch June 2030 (1) Phase 4 Atopic Dermatitis Not yet recruiting
Est. primary completion 2030-06-01 ·
NCT07352566 ·
CT.gov ↗ What to watch July 2030 (1) Phase 3 Atopic Dermatitis Recruiting
Est. primary completion 2030-07 ·
NCT06461897 ·
CT.gov ↗ What to watch 2032 (1) March 2032 (1) Phase 3 Severe Alopecia Areata Recruiting
Est. primary completion 2032-03 ·
NCT07772492 ·
CT.gov ↗ What to watch See the full readout calendar ↗
All registered studies Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.
All indications (99) Rheumatoid Arthritis (21) Atopic Dermatitis (17) Ulcerative Colitis (12) Crohn's Disease (11) Psoriatic Arthritis (4) Systemic Lupus Erythematosus (3) Other / comorbidity (32)
Phase 3 (46) Phase 2/3 (2) Phase 2 (21) Phase 1/2 (2) Phase 1 (7) Phase 4 (19) Early phase / not applicable (2) Appears in other studies (1)